Home » Stocks » VYNT

Vyant Bio, Inc. (VYNT)

Stock Price: $4.02 USD -0.16 (-3.83%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $3.98 -0.04 (-1.00%) Apr 9, 7:37 PM
Market Cap 120.58M
Revenue (ttm) 5.75M
Net Income (ttm) -8.00M
Shares Out 2.53M
EPS (ttm) -3.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $4.02
Previous Close $4.18
Change ($) -0.16
Change (%) -3.83%
Day's Open 4.15
Day's Range 3.94 - 4.32
Day's Volume 619,120
52-Week Range 2.11 - 17.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-bas...

4 days ago - GlobeNewsWire

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-base...

1 week ago - GlobeNewsWire

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

Other stocks mentioned: CGIX
1 week ago - GlobeNewsWire

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline o...

Other stocks mentioned: CGIX
2 weeks ago - GlobeNewsWire

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

Other stocks mentioned: CGIX
4 weeks ago - GlobeNewsWire

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

Other stocks mentioned: CGIX
1 month ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
1 month ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
1 month ago - GlobeNewsWire

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...

Other stocks mentioned: USNA, ABCL, AZRX, CGIX
1 month ago - Benzinga

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket...

Other stocks mentioned: CGIX
1 month ago - InvestorPlace

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
2 months ago - GlobeNewsWire

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

Other stocks mentioned: CGIX
2 months ago - GlobeNewsWire

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief E...

Other stocks mentioned: CGIX
3 months ago - GlobeNewsWire

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX" or the "C...

Other stocks mentioned: CGIX
4 months ago - PRNewsWire

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced toda...

Other stocks mentioned: CGIX
4 months ago - GlobeNewsWire

Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology ser...

Other stocks mentioned: CGIX
5 months ago - GlobeNewsWire

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ...

Other stocks mentioned: CGIX
5 months ago - GlobeNewsWire

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services, announc...

Other stocks mentioned: CGIX
5 months ago - GlobeNewsWire

MUMBAI, India and LONDON, Sept. 28, 2020 /PRNewswire/ -- A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has shown tha...

Other stocks mentioned: CGIX
6 months ago - PRNewsWire

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger wi...

Other stocks mentioned: CGIX
6 months ago - PRNewsWire

RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today annou...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and St...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Cit...

Other stocks mentioned: CGIX
7 months ago - PRNewsWire

NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc.

Other stocks mentioned: CGIX
7 months ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Other stocks mentioned: CGIX
7 months ago - Business Wire

Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.

Other stocks mentioned: CGIX
7 months ago - Newsfile Corp

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc.

Other stocks mentioned: CGIX
7 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc.

Other stocks mentioned: CGIX
7 months ago - Newsfile Corp

Cancer Genetics (NASDAQ: CGIX) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX.

Other stocks mentioned: CGIX
7 months ago - Benzinga

Cancer Genetics Inc. (NASDAQ: CGIX) shares more than doubled on Monday after the company announced a merger with StemoniX.

Other stocks mentioned: CGIX
7 months ago - 24/7 Wall Street

Cancer Genetics' news of a merger with major drug developer StemoniX has CGIX stock skyrocketing higher on Monday morning. The post Cancer Genetics News: Why CGIX Stock Is Rocketing Today appeared first...

Other stocks mentioned: CGIX
7 months ago - InvestorPlace

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ye...

Other stocks mentioned: CGIX
7 months ago - GlobeNewsWire

Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings and capital...

Other stocks mentioned: AHCO, ARAV, CGIX, GNUS, NOVA, PAYS, RMBL
9 months ago - 24/7 Wall Street

RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announ...

Other stocks mentioned: CGIX
9 months ago - GlobeNewsWire

RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology s...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

Note Payment Received from Interpace Diagnostics Group, Inc.

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will ...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...

Other stocks mentioned: CGIX
1 year ago - GlobeNewsWire

Cancer Genetics (NASDAQ: CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.

Other stocks mentioned: CGIX
1 year ago - Benzinga

About VYNT

There is no company description available.

Industry
Medical Laboratories
IPO Date
Apr 5, 2013
CEO
John Roberts
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
VYNT
Full Company Profile

Financial Performance

In 2020, Vyant Bio's revenue was $5.75 million, a decrease of -21.27% compared to the previous year's $7.31 million. Losses were -$8.00 million, 19.3% more than in 2019.

Financial Statements